- Home
- DXC vs PSNL Comparison
DXC vs PSNL Comparison
Compare DXC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | PSNL |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | 115000 | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXC | PSNL |
|---|---|---|
| Price | $10.39 | $13.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $15.00 | $12.20 |
| AVG Volume (30 Days) | ★ 3.8M | 3.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $12,644,000,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $14.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.90 | $4.45 |
| 52 Week High | $15.68 | $16.39 |
Technical Indicators
Market Signals| Indicator | DXC | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 57.08 |
| Support Level | $7.92 | $6.89 |
| Resistance Level | $10.66 | $14.81 |
| Average True Range (ATR) | 0.58 | 0.59 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 9.18 | 79.03 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.